In the past week, SWTX stock has gone down by -5.43%, with a monthly decline of -10.46% and a quarterly plunge of -23.48%. The volatility ratio for the week is 3.22%, and the volatility levels for the last 30 days are 4.02% for SpringWorks Therapeutics Inc. The simple moving average for the past 20 days is -6.30% for SWTX’s stock, with a -28.88% simple moving average for the past 200 days.
Is It Worth Investing in SpringWorks Therapeutics Inc (NASDAQ: SWTX) Right Now?
The stock has a 36-month beta value of 0.79. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SWTX is 66.98M, and at present, short sellers hold a 18.18% of that float. On October 25, 2024, the average trading volume of SWTX was 924.06K shares.
SWTX) stock’s latest price update
SpringWorks Therapeutics Inc (NASDAQ: SWTX)’s stock price has gone rise by 1.75 in comparison to its previous close of 28.61, however, the company has experienced a -5.43% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-10-22 that STAMFORD, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 12, 2024 to report its third quarter financial results and discuss recent business updates.
Analysts’ Opinion of SWTX
Many brokerage firms have already submitted their reports for SWTX stocks, with Guggenheim repeating the rating for SWTX by listing it as a “Buy.” The predicted price for SWTX in the upcoming period, according to Guggenheim is $75 based on the research report published on February 05, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see SWTX reach a price target of $45. The rating they have provided for SWTX stocks is “Buy” according to the report published on December 01st, 2022.
H.C. Wainwright gave a rating of “Buy” to SWTX, setting the target price at $101 in the report published on January 19th of the previous year.
SWTX Trading at -17.05% from the 50-Day Moving Average
After a stumble in the market that brought SWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.01% of loss for the given period.
Volatility was left at 4.02%, however, over the last 30 days, the volatility rate increased by 3.22%, as shares sank -9.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.98% lower at present.
During the last 5 trading sessions, SWTX fell by -5.43%, which changed the moving average for the period of 200-days by -29.72% in comparison to the 20-day moving average, which settled at $31.07. In addition, SpringWorks Therapeutics Inc saw -20.25% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SWTX starting from Islam Saqib, who sale 49,000 shares at the price of $40.57 back on Sep 03 ’24. After this action, Islam Saqib now owns 1,063,368 shares of SpringWorks Therapeutics Inc, valued at $1,988,033 using the latest closing price.
Edris Badreddin, the Chief Operating Officer of SpringWorks Therapeutics Inc, sale 20,000 shares at $40.65 during a trade that took place back on Sep 03 ’24, which means that Edris Badreddin is holding 229,600 shares at $812,954 based on the most recent closing price.
Stock Fundamentals for SWTX
Current profitability levels for the company are sitting at:
- -3.5 for the present operating margin
- 0.92 for the gross margin
The net margin for SpringWorks Therapeutics Inc stands at -3.28. The total capital return value is set at -0.57. Equity return is now at value -59.72, with -53.07 for asset returns.
Based on SpringWorks Therapeutics Inc (SWTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -33.13. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -75.09.
Currently, EBITDA for the company is -341.35 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 22.77. The receivables turnover for the company is 3.75for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.91.
Conclusion
To sum up, SpringWorks Therapeutics Inc (SWTX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
